Aerocrine’s NIOX MINO® device for measuring FeNO receives approval by Health Canada
SOLNA, Sweden – 16 April, 2013 - Aerocrine AB (OMX Nordic Exchange: AERO) announces that Health Canada’s Therapeutic Products Directorate has authorized Aerocrine’s latest NIOX MINO® for use in identifying allergic airway inflammation.
NIOX MINO measures fractional exhaled nitric oxide (FeNO) which is a direct, non-invasive way to assess the allergic airway inflammation which characterizes many adults and children with asthma. Physicians use FeNO to identify allergic airway inflammation in patients with suspected asthma, to help predict patient response to corticosteroid therapy, as well as to help assess adherence to corticosteroid therapy.
According to the Canadian Asthma Society, asthma affects approximately three million Canadians and thirteen percent of Canadian children. Asthma is also the leading cause of absenteeism from school and is the primary reason for emergency room visits among school age children. As stated in the Canadian Asthma Guidelines, the goal of asthma management is to reduce airway inflammation.
“This device provides me with a measurement of allergic airway inflammation that is non-invasive and is an easy 10-second test for patients,” said Dr. Harold Kim, allergist in Kitchener, Ontario, with appointment at McMaster University. “Asthma is by definition a chronic inflammatory disease of the airways and this test adds a new dimension in managing patients that routine available tests are not able to provide.”
“The approval in Canada is another step forward for Aerocrine and means that Aerocrine’s innovative technology will now be available throughout North America. We are actively evaluating our distribution needs in Canada in light of this important approval,” said Ken Marshall, President Aerocrine, Inc.
Asthma is a chronic inflammatory disease of the airways characterized by symptoms including wheezing, cough and shortness of breath. The disease affects more than 300 million people around the world, many of whom are children. Asthma is a complex disease for which there is no cure. Current therapy is focused on controlling the disease.
For more information, contact:
Ken Marshall, President, Aerocrine Inc., Phone: 1 (919) 280 9687
Kathy Hodgdon, Sr Director, Business Development, Alternate Channels, Phone: 1 (314) 566 8546
Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: 1 (970) 368 0336 or +46 768 788 379
Aerocrine AB is a medical products company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO®. This product enables fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007.
Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8:00 a.m. on April 16, 2013